The purpose of this study is to compare the incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications.

Inclusion Criteria:

• Signed informed consent
• Diagnosis of rheumatoid arthritis
• > 18 years at index treatment initiation or switch
• Starting treatment with abatacept or new disease-modifying anti-rheumatic drug (including switching or adding) or biologic disease modifying drug.
• Read/write English

Exclusion Criteria:

• None

Patients being treated for rheumatoid arthritis in the US